# Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis

> **NCT05177835** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Abivax S.A.** · enrollment: 203 (estimated)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** ABX464

## Key facts

- **NCT ID:** NCT05177835
- **Lead sponsor:** Abivax S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-03
- **Primary completion:** 2028-03
- **Final completion:** 2028-04
- **Target enrollment:** 203 (ESTIMATED)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05177835

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05177835, "Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT05177835. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*